statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

YARDLEY, Pa., April 04, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...

Optinose to Present at the Needham Virtual Healthcare Conference

OptiNose, Inc. (NASDAQ:OPTN  Get Free Report) CEO Ramy A. Mahmoud sold 19,198 shares of the stock in a transaction that occurred on Monday, March 18th. The shares were sold at an average price...

Ramy A. Mahmoud Sells 19,198 Shares of OptiNose, Inc. (NASDAQ:OPTN) Stock

OptiNose (NASDAQ:OPTN  Free Report) had its price target raised by Lake Street Capital from $3.00 to $4.00 in a report published on Monday, Benzinga reports. The brokerage currently has a buy...

OptiNose (NASDAQ:OPTN) PT Raised to $4.00

OptiNose (NASDAQ:OPTN  Free Report) had its price target raised by Lake Street Capital from $3.00 to $4.00 in a research note issued to investors on Monday, Benzinga reports. The brokerage...

Lake Street Capital Boosts OptiNose (NASDAQ:OPTN) Price Target to $4.00

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Optinose price target raised by $1 at Lake Street, here's why

Matthew Caufield, an analyst from H.C. Wainwright, reiterated the Buy rating on Optinose (OPTN Research Report). The associated price target is...

Optinose's XHANCE Expands Market Reach with FDA Label Extension: A Comprehensive Analysis

OptiNose granted FDA nod to expand labeling for sinusitis therapy...

OptiNose granted FDA nod to expand labeling for sinusitis therapy

OptiNose trading resumes

Optinose to resume trading at 4:20 pm ET

ReOpen was the first ever large placebo-controlled clinical trial program to demonstrate statistically significant reduction of symptoms in chronic sinusitis patients without nasal polyps Clinical...

XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal Polyps

OptiNose, Inc. operates as a pharmaceutical company. The firm engages in the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists. Its products include the XHANCE and ONZETRA Xsail. The company was founded by Per Gisle Djupesland and Helena Kyttari Djupesland in October 2000 and is headquartered in Yardley, PA.

Watchers	1,939
52-Wk Low	$0.80
52-Wk High	$2.10

Volume	84,185.00
52-Wk High	$2.10
52-Wk Low	$0.80

Period	Estimated	Reported	Surprise	Result
Q2'24	-$0.08	--	--	N/A
Q1'24	-$0.11	-$0.12	-12.94%	MISSED
Q4'23	-$0.09	-$0.09	4.66%	BEAT
Q3'23	-$0.09	-$0.08	15.21%	BEAT
Q2'23	-$0.11	$0.02	118.43%	BEAT

OPTN OptiNose Inc

About

Feed

News

Sentiment

Earnings

Fundamentals